Sign in
Taking peoplePhase 4

Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster

Key facts

Who runs it
Peking University Third Hospital
Where
China4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
140 people, planned
Started
25 Aug 2025
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Brivudine
  • Famciclovir
Record updated
2 January 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Age ≥18 years, regardless of gender
  • Signed Informed Consent Form
  • Female subjects must not plan for pregnancy or oocyte donation from screening until 1 week after the last dose and must voluntarily adopt highly effective physical contraception; male subjects must not plan for fertility or sperm donation during the same period and must voluntarily adopt highly effective physical contraception. Methods include:; Barrier methods: Condom or barrier cap (diaphragm or cervical cap); Intrauterine device (IUD) or intrauterine system (IUS); Surgical sterilization (bilateral oophorectomy with/without hysterectomy, total hysterectomy, bilateral tubal ligation, or vasectomy) performed ≥6 months prior to the first dose in the subject or their partner; Other investigator-confirmed highly effective physical contraception

Who cannot take part

  • Allergy to brivudine, famciclovir, or penciclovir
  • Cancer patients currently undergoing chemotherapy
  • Parkinson's disease
  • Any condition deemed inappropriate for study participation by the investigator
  • Current use of fluorouracil agents (e.g., 5-fluorouracil, capecitabine, tegafur, flucytosine)
  • Pregnant or lactating women

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Herpes zoster

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This multicenter RCT aims to compare the efficacy and safety of Brivudine versus Famciclovir in treating acute herpes zoster. Primary objective: Evaluate pain reduction via Numeric Pain Rating Scale (NPRS) at Day 30. Secondary objectives: Compare NPRS at Day 3/Day 7/Day 14/Day 90, time to lesion resolution, Postherpetic Neuralgia (PHN) incidence, and safety.

The 2 groups in the trial

  • Brivudine GroupTreatment being tested

    Treatment: Brivudine

  • Famciclovir GroupExisting treatment, for comparison

    Treatment: Famciclovir

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster: A Multicenter, Randomized, Prospective Clinical Trial
Criteria questions
Built from NCT07099157, who can take part
Record updated
2 January 2026